Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

A breast cancer diagnosis often arrives as a profound turning point, bringing uncertainty and complex emotions. While the ...

Author, speaker and health content creator Dr Liz O’Riordan shares her journey from consultant breast surgeon to cancer ...

Her employer said a contract is only ended when "all other options have been exhausted and a robust process has been followed ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

Time is important with a cancer diagnosis so that treatment can be started early before cancer spreads.” - Dr. Hazem Abdel Samie, Managing Director of MSD Egypt ClusterCAIRO, EGYPT, January 31, 2025 ...

Major medical initiatives to bolster Saudi Arabia’s healthcare sector have been unveiled this week, including a state-of-the-art oncology center and a huge ...

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

The model of care the medical world is moving towards gives priority to patient-centred approaches and ensures every treatment plan is unique ...

In speech prepared by Narendra Modi government, the President was, of course, talking about State health care. But the ...

Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...